i-GONAD: a robust method for in situ germline genome engineering using CRISPR nucleases

Masato Ohtsuka,Masahiro Sato,Hiromi Miura,Shuji Takabayashi,Makoto Matsuyama,Takayuki Koyano,Naomi Arifin,Shingo Nakamura,Kenta Wada,Channabasavaiah B. Gurumurthy
DOI: https://doi.org/10.1186/s13059-018-1400-x
IF: 17.906
2018-02-26
Genome Biology
Abstract:We present a robust method called improved-Genome editing via Oviductal Nucleic Acids Delivery (i-GONAD) that delivers CRISPR ribonucleoproteins to E0.7 embryos via in situ electroporation. The method generates mouse models containing single-base changes, kilobase-sized deletions, and knock-ins. The efficiency of i-GONAD is comparable to that of traditional microinjection methods, which rely on ex vivo handling of zygotes and require recipient animals for embryo transfer. In contrast, i-GONAD avoids these technically difficult steps, and it can be performed at any laboratory with simple equipment and technical expertise. Further, i-GONAD-treated females retain reproductive function, suggesting future use of the method for germline gene therapy.
genetics & heredity,biotechnology & applied microbiology
What problem does this paper attempt to address?